Braintree Scientific, Inc. – Trademark Portfolio
Entity Type: 03
Braintree Scientific, Inc. holds 4 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 10 (Medical Apparatus) — 2 filings in this category. The portfolio also extends into Class 1 (Chemicals) across 3 Nice Classification classes. Currently, 4 trademarks are registered. Notable registered marks include DECAPICONE, DELTAPHASE, ARMOR TOUCH, and MICRO-RENATHANE. The owner is based in Braintree, MA.
60 Columbian Street West
P.O. Box 850498
Braintree, MA 02185
Showing of trademarks Trademarks
Trademark Classifications
Braintree Scientific, Inc.'s trademark portfolio spans 3 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Chemical products for industry, science, photography, agriculture, horticulture and forestry
Scientific, nautical, surveying, photographic, cinematographic, optical apparatus and instruments
Frequently Asked Questions
How many trademarks does Braintree Scientific, Inc. have?
Braintree Scientific, Inc. has 4 U.S. trademarks filed with the USPTO. Of these, 4 registered.
What trademark classes does Braintree Scientific, Inc. file in?
Braintree Scientific, Inc. files trademarks across 3 Nice Classification classes. The most active classes are Class 10 (Medical Apparatus), Class 1 (Chemicals), Class 9 (Computers & Electronics). Class 10 covers surgical, medical, dental and veterinary apparatus and instruments.
What are Braintree Scientific, Inc.'s most well-known trademarks?
Braintree Scientific, Inc.'s registered trademark portfolio includes well-known marks such as DECAPICONE, DELTAPHASE, ARMOR TOUCH, and MICRO-RENATHANE. These are among 4 currently registered trademarks in the portfolio.
What is Braintree Scientific, Inc.'s trademark registration success rate?
Braintree Scientific, Inc. has a 100% trademark registration rate, with 4 out of 4 resolved applications resulting in successful registration. Currently, 0 applications are pending review.